CD4 T cells in tumor immunity

@article{Gerloni2004CD4TC,
  title={CD4 T cells in tumor immunity},
  author={Mara Gerloni and Maurizio Zanetti},
  journal={Springer Seminars in Immunopathology},
  year={2004},
  volume={27},
  pages={37-48}
}
T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in protective anti-tumor responses has received growing attention. Here we will discuss the role of MHC class II-restricted T cells in response to, and in the regulation of, tumor antigens. Emphasis will be… 
Tumor-specific Th17-polarized cells eradicate large established melanoma.
TLDR
Data indicate that the appropriate in vitro polarization of effector CD4+ T cells is decisive for successful tumor eradication, and this principle should be considered in designing clinical trials involving adoptive transfer-based immunotherapy of human malignancies.
MHC class II molecules and tumour immunotherapy
TLDR
These data suggest that it may be necessary to involve both CD4+ and CD8+ T cells for more effective antitumour therapy, and that vaccines against cancers aim to induce tumour-specific effector T cells that can reduce tumour mass and induce development of tumours-specific T cell memory, that can control tumour relapse.
NK 1 . 1 + cells are important for the development of protective immunity against MHC I-deficient , HPV 16-associated tumours
TLDR
It is demonstrated that the development of immunity against MHC class I-deficient tumours is highly dependent on the activity NK1.1+ cell population, which is significantly abrogated by TC-1 cell immunization.
Th 9 cells promote antitumor immune responses in vivo
TLDR
The data suggest a distinct role for tumor-specific Th9 cells in provoking CD8+ CTL-mediated antitumor immunity and indicate that Th9 cell–based cancer immunotherapy may be a promising therapeutic approach.
The Cooperation between Two CD4 T Cells Induces Tumor Protective Immunity in MUC.1 Transgenic Mice1
TLDR
It is concluded that immunity against tumor self-Ags and tumor protection can be regulated exploiting an inherent property of the immune system.
HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation
TLDR
The concept of altered HLA expression as a mechanism exploited by tumors to escape immune control and induce an immunosuppressive environment is reviewed.
Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
TLDR
The role and regulation of CD4 T cells in response to tumor Ags is discussed, and emphasis is placed on the types of Ags and mechanisms that elicit tumor-protective responses.
Monoclonal T-cell receptors: new reagents for cancer therapy.
TLDR
The demonstration that cloned T-cell receptor (TCR) genes can be used to produce T lymphocyte populations of desired specificity offers new opportunities for antigen-specific T- cell therapy, and sequence modifications of TCR genes are being explored to enhance TCR surface expression.
...
...

References

SHOWING 1-10 OF 88 REFERENCES
The Central Role of CD4+ T Cells in the Antitumor Immune Response
TLDR
Analysis of the effector phase of tumor rejection induced by vaccination with irradiated tumor cells transduced to secrete granulocyte/macrophage colony-stimulating factor indicates a far broader role for CD4+ T cells in orchestrating the host response to tumor.
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
TLDR
Removal of immunoregulatory CD25+4+ T cells can abrogate immunological unresponsiveness to syngeneic tumors in vivo and in vitro, leading to spontaneous development of tumor-specific effector cells as well as tumor-nonspecific ones.
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
TLDR
The results demonstrate that T-cell help is ‘programmed’ into CD8+ T cells during priming, conferring on these cells a hallmark of immune response memory: the capacity for functional expansion on re-encounter with antigen.
Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors
This study shows that induction of tumor-specific CD4+ T cells by vaccination with a specific viral T helper epitope, contained within a synthetic peptide, results in protective immunity against
CD4+CD25+ Suppressor Lymphocytes in the Circulation of Patients Immunized Against Melanoma Antigens
TLDR
It is demonstrated that anergic and functionally suppressive CD4+CD25+ T cells exist in patients with melanoma undergoing tumor antigen immunization and thus may play a role in modifying the magnitude of the T cell response to immunization.
Activation of CD4 T cells by somatic transgenesis induces generalized immunity of uncommitted T cells and immunologic memory.
TLDR
These studies provide evidence that by initiating immunity directly in secondary lymphoid organs, an immune response is generated with characteristics that differ from those using vaccines of conventional DNA or protein in adjuvant administered in peripheral sites.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TLDR
It is shown, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor T Reg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo.
Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.
TLDR
The results suggest that lambda 2(315) is processed and presented by host antigen-presenting cells, which in turn activate naive, idiotype-specific T cells.
Interleukin 7 induces CD4+ T cell-dependent tumor rejection
TLDR
It is demonstrated that a high local IL-7 concentration at the tumor site obtained by tumor cell-targeted gene transfer leads to tumor rejection involving a cellular mechanism that seems to be different from the ones observed in analogous experiments with other cytokines.
...
...